Rather, the potential therapy proposed in this study aimed at normalizing the TGF-β signaling by reducing the activity of a pro-metastatic signaling pathway from an hyperactivated state, seen in highly-invasive breast cancer cells towards near-normal levels seen in poorly-metastatic breast cancer cells. Here, TGFB1 is linked to breast carcinoma.